Specialty Retail
Compare Stocks
2 / 10Stock Comparison
EYE vs HSIC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
EYE vs HSIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Specialty Retail | Medical - Distribution |
| Market Cap | $1.81B | $8.09B |
| Revenue (TTM) | $1.99B | $13.18B |
| Net Income (TTM) | $30M | $398M |
| Gross Margin | 56.5% | 29.1% |
| Operating Margin | 3.0% | 5.8% |
| Forward P/E | 32.6x | 13.3x |
| Total Debt | $695M | $3.69B |
| Cash & Equiv. | $39M | $156M |
EYE vs HSIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| National Vision Hol… (EYE) | 100 | 85.3 | -14.7% |
| Henry Schein, Inc. (HSIC) | 100 | 116.1 | +16.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EYE vs HSIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EYE is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.62
- Rev growth 9.0%, EPS growth 202.8%, 3Y rev CAGR 6.5%
- 9.0% revenue growth vs HSIC's 4.0%
HSIC carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 5.3% 10Y total return vs EYE's -18.0%
- Lower volatility, beta 0.73, Low D/E 76.9%, current ratio 1.38x
- Beta 0.73, current ratio 1.38x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.0% revenue growth vs HSIC's 4.0% | |
| Value | Lower P/E (13.3x vs 32.6x) | |
| Quality / Margins | 3.0% margin vs EYE's 1.5% | |
| Stability / Safety | Beta 0.73 vs EYE's 1.62, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +46.3% vs HSIC's +5.9% | |
| Efficiency (ROA) | 3.6% ROA vs EYE's 1.5%, ROIC 7.1% vs 3.0% |
EYE vs HSIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EYE vs HSIC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — EYE and HSIC each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 6.6x EYE's $2.0B. Profitability is closely matched — net margins range from 3.0% (HSIC) to 1.5% (EYE). On growth, EYE holds the edge at +15.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.0B | $13.2B |
| EBITDAEarnings before interest/tax | $153M | $1.1B |
| Net IncomeAfter-tax profit | $30M | $398M |
| Free Cash FlowCash after capex | $73M | $561M |
| Gross MarginGross profit ÷ Revenue | +56.5% | +29.1% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +5.8% |
| Net MarginNet income ÷ Revenue | +1.5% | +3.0% |
| FCF MarginFCF ÷ Revenue | +3.7% | +4.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.1% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +111.3% | +14.9% |
Valuation Metrics
HSIC leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 65% valuation discount to EYE's 61.7x P/E. On an enterprise value basis, HSIC's 10.9x EV/EBITDA is more attractive than EYE's 16.2x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.8B | $8.1B |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | 61.70x | 21.56x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.60x | 13.26x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.84x |
| EV / EBITDAEnterprise value multiple | 16.20x | 10.87x |
| Price / SalesMarket cap ÷ Revenue | 0.91x | 0.61x |
| Price / BookPrice ÷ Book value/share | 2.12x | 1.79x |
| Price / FCFMarket cap ÷ FCF | 24.68x | 14.12x |
Profitability & Efficiency
HSIC leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HSIC delivers a 8.2% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $3 for EYE. HSIC carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to EYE's 0.80x. On the Piotroski fundamental quality scale (0–9), EYE scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +3.5% | +8.2% |
| ROA (TTM)Return on assets | +1.5% | +3.6% |
| ROICReturn on invested capital | +3.0% | +7.1% |
| ROCEReturn on capital employed | +3.8% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.80x | 0.77x |
| Net DebtTotal debt minus cash | $656M | $3.5B |
| Cash & Equiv.Liquid assets | $39M | $156M |
| Total DebtShort + long-term debt | $695M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 3.54x | 4.59x |
Total Returns (Dividends Reinvested)
Evenly matched — EYE and HSIC each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HSIC five years ago would be worth $8,746 today (with dividends reinvested), compared to $4,462 for EYE. Over the past 12 months, EYE leads with a +46.3% total return vs HSIC's +5.9%. The 3-year compound annual growth rate (CAGR) favors EYE at 0.7% vs HSIC's -4.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -12.0% | -8.2% |
| 1-Year ReturnPast 12 months | +46.3% | +5.9% |
| 3-Year ReturnCumulative with dividends | +2.2% | -11.7% |
| 5-Year ReturnCumulative with dividends | -55.4% | -12.5% |
| 10-Year ReturnCumulative with dividends | -18.0% | +5.3% |
| CAGR (3Y)Annualised 3-year return | +0.7% | -4.0% |
Risk & Volatility
HSIC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HSIC is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than EYE's 1.62 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.62x | 0.73x |
| 52-Week HighHighest price in past year | $30.02 | $89.29 |
| 52-Week LowLowest price in past year | $14.38 | $61.95 |
| % of 52W HighCurrent price vs 52-week peak | +76.0% | +79.0% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 1.2M |
Analyst Outlook
EYE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates EYE as "Buy" and HSIC as "Hold". Consensus price targets imply 54.2% upside for EYE (target: $35) vs 22.6% for HSIC (target: $86).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $35.20 | $86.43 |
| # AnalystsCovering analysts | 14 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +10.5% |
HSIC leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). EYE leads in 1 (Analyst Outlook). 2 tied.
EYE vs HSIC: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is EYE or HSIC a better buy right now?
For growth investors, National Vision Holdings, Inc.
(EYE) is the stronger pick with 9. 0% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate National Vision Holdings, Inc. (EYE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EYE or HSIC?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus National Vision Holdings, Inc. at 61. 7x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x.
03Which is the better long-term investment — EYE or HSIC?
Over the past 5 years, Henry Schein, Inc.
(HSIC) delivered a total return of -12. 5%, compared to -55. 4% for National Vision Holdings, Inc. (EYE). Over 10 years, the gap is even starker: HSIC returned +5. 3% versus EYE's -18. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EYE or HSIC?
By beta (market sensitivity over 5 years), Henry Schein, Inc.
(HSIC) is the lower-risk stock at 0. 73β versus National Vision Holdings, Inc. 's 1. 62β — meaning EYE is approximately 121% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 80% for National Vision Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EYE or HSIC?
By revenue growth (latest reported year), National Vision Holdings, Inc.
(EYE) is pulling ahead at 9. 0% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: National Vision Holdings, Inc. grew EPS 202. 8% year-over-year, compared to 7. 2% for Henry Schein, Inc.. Over a 3-year CAGR, EYE leads at 6. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EYE or HSIC?
Henry Schein, Inc.
(HSIC) is the more profitable company, earning 3. 0% net margin versus 1. 5% for National Vision Holdings, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus 3. 1% for EYE. At the gross margin level — before operating expenses — EYE leads at 54. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EYE or HSIC more undervalued right now?
On forward earnings alone, Henry Schein, Inc.
(HSIC) trades at 13. 3x forward P/E versus 32. 6x for National Vision Holdings, Inc. — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EYE: 54. 2% to $35. 20.
08Which pays a better dividend — EYE or HSIC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is EYE or HSIC better for a retirement portfolio?
For long-horizon retirement investors, Henry Schein, Inc.
(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). National Vision Holdings, Inc. (EYE) carries a higher beta of 1. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 3%, EYE: -18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EYE and HSIC?
These companies operate in different sectors (EYE (Consumer Cyclical) and HSIC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.